Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in
participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion.
The main question[s] it aims to answer is if the use of bortezomib will result in a decline
in PSA for participants.
Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles. Each cycle
is about 21 days.